Conclusion
The findings demonstrate that having access to datasets in the OMOP-CDM
format facilitates RWD analysis and can be useful for gleaning insights
on comparative drug utilization, efficacy and safety, for risk-benefit
assessments. While the initial conversion is challenging and needs to be
done judiciously, the availability of a community of researchers and the
sharing of previously written analytic code which serve as templates
makes the process worthwhile. The ability to refine previously developed
analytic codes with simple modifications is an important step in
harnessing RWD to supplement benefit-risk assessments and creates a
perpetual cycle of tool refinement needed to address the challenges of
generating valuable insights from RWD and enable the conduct of robust
evaluations on post-market drug efficacy and safety use cases, and
ultimately make evidence-based decisions to optimise health outcomes.